iBio, Inc. (IBIO)
IBIO Stock Price Chart
Explore iBio, Inc. interactive price chart. Choose custom timeframes to analyze IBIO price movements and trends.
IBIO Company Profile
Discover essential business fundamentals and corporate details for iBio, Inc. (IBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Aug 2008
Employees
16.00
Website
https://www.ibioinc.comCEO
Martin Brenner
Description
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
IBIO Financial Timeline
Browse a chronological timeline of iBio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Sept 2026
EPS estimate is -$0.06, while revenue estimate is $80.00k.
Upcoming earnings on 4 Sept 2026
EPS estimate is -$0.07, while revenue estimate is $33.33k.
Earnings released on 12 May 2026
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%.
Earnings released on 10 Feb 2026
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 12 Nov 2025
EPS came in at -$0.11 falling short of the estimated -$0.07 by -57.14%, while revenue for the quarter reached $100.00k , beating expectations by +200.00%.
Earnings released on 5 Sept 2025
EPS came in at -$0.31 surpassing the estimated -$0.39 by +20.51%, while revenue for the quarter reached $200.00k , beating expectations by +100.00%.
Earnings released on 2 May 2025
EPS came in at -$0.49 falling short of the estimated -$0.39 by -25.64%.
Earnings released on 10 Feb 2025
EPS came in at -$0.48 falling short of the estimated -$0.45 by -6.67%, while revenue for the quarter reached $200.00k .
Earnings released on 12 Nov 2024
EPS came in at -$0.46 matching the estimated -$0.46.
Earnings released on 25 Sept 2024
EPS came in at -$0.91 falling short of the estimated -$0.47 by -93.62%, while revenue for the quarter reached $175.00k .
Earnings released on 13 May 2024
EPS came in at -$0.71 .
Earnings released on 9 Feb 2024
EPS came in at -$2.42 .
Stock split effective on 29 Nov 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$4.20 , while revenue for the quarter reached $50.00k .
Earnings released on 27 Sept 2023
EPS came in at $0.26 surpassing the estimated -$0.41 by +163.41%.
Earnings released on 11 May 2023
EPS came in at -$6.61 falling short of the estimated -$3.42 by -93.36%, while revenue for the quarter reached $200.00k , meeting expectations.
Earnings released on 14 Feb 2023
EPS came in at -$21.60 surpassing the estimated -$146.90 by +85.30%.
Earnings released on 14 Nov 2022
EPS came in at -$2.05 falling short of the estimated -$1.85 by -10.81%, while revenue for the quarter reached $56.00k , missing expectations by -90.67%.
Earnings released on 11 Oct 2022
EPS came in at -$1.96 surpassing the estimated -$2.12 by +7.55%, while revenue for the quarter reached $61.00k , missing expectations by -75.60%.
Stock split effective on 10 Oct 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2022
EPS came in at -$30.00 falling short of the estimated -$1.25 by -2.30k%, while revenue for the quarter reached $1.94m , beating expectations by +871.50%.
Earnings released on 14 Feb 2022
EPS came in at -$25.00 falling short of the estimated -$1.00 by -2.40k%, while revenue for the quarter reached $168.00k , missing expectations by -32.80%.
Earnings released on 15 Nov 2021
EPS came in at -$20.00 falling short of the estimated -$1.25 by -1.50k%, while revenue for the quarter reached $211.00k , missing expectations by -29.67%.
Earnings released on 27 Sept 2021
EPS came in at -$25.00 , while revenue for the quarter reached $491.00k .
IBIO Stock Performance
Access detailed IBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
